UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, DCD.C. 20549

FORM 8-K

CURRENT REPORT ~~PURSUANT~~

TOPursuant ~~SECTION~~to Section 13 ORor 15(Dd) OFof ~~THE~~the Securities and Exchange Act of 1934

~~SECURITIES~~Date ~~EXCHANGE~~of ~~ACT~~Report OF(date ~~1934~~of earliest event reported): May 3, 2023

Date of report (Date of earliest event reported): March 23, 2023

Tengjun Biotechnology Corp.

(Exact name of registrant as specified in its charter)

Nevada	333-169397	27-3042462
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification Number)

East Jinze Road and South Huimin Road, ~~Food~~ Food Industry Economic and Technology Development District, ~~Jinxiang County, Jining City, Shandong Province, China~~

~~(Address~~Jinxiang ofCounty, ~~Principal~~Jining ~~Executive~~City, ~~Offices)~~Shandong Province, China

(~~86) 0537-8711599~~Address ~~(Registrant’s~~of ~~Telephone~~principal ~~Number,~~executive ~~Including~~offices ~~Area~~and ~~Code~~zip code)

(86) 0537-8711599

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:		Trading Symbol(s)		Name of each exchange on which registered:
None		None		None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~13(a)~~Item of8.01 ~~the~~Other ~~Exchange Act~~Events. ☐

~~Item~~On May 43, 2023, Tengjun Biotechnology Corp.01 ~~CHANGES~~(the IN“Company”) ~~REGISTRANT~~conducted its second and final closing of the public offering of its common stock pursuant to the Company’s registration statement on Form S-1 ~~CERTIFYING~~(File ~~ACCOUNTANT~~No. 333-266300) initially filed with the Securities and Exchange Commission (“Commission”) on July 22, 2022 and declared effective on November 4, 2022 (the “Registration Statement”), whereby the Company offered and sold additional 1,402,027 shares of common stock (the “Shares”) at $1.00 per share for a total purchase price of $1,402,027 from the investors. Together with the 3,000,000 Shares issued and sold pursuant to the initial closing on January 9, 2023 raising $3,000,000, the Company offered and sold an aggregate of 4,402,027 shares of common stock for a total of $4,402,027 under the public offering pursuant to the Registration Statement as of May 3, 2023.

On March 23, 2023, Tengjun Biotechnology Corp., a company incorporated under the laws of the State of Nevada (the “Company”), elected not to continue the engagement of KCCW Accountancy Corp. (“KCCW”) serving as the Company’s independent registered public accounting firm. The termination of the engagement of KCCW has been approved by the Board of Directors of the Company (the “Board”).1

The report of KCCW on the financial statements of the Company as of and for the fiscal year ended December 31, 2021 did not contain any adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles.SIGNATURES

~~During~~Pursuant to the ~~Company’s most recent fiscal year~~requirements ~~and~~of the ~~subsequent~~Securities ~~interim~~Exchange ~~period~~Act ~~through March 23, 2023 there were no disagreements with KCCW on any matter~~ of ~~accounting principles or practices~~1934, ~~financial~~as ~~statement disclosure~~amended, ~~or auditing scope or procedure, which disagreement(s), if not resolved to~~ the ~~satisfaction of~~Registrant ~~KCCW,~~has ~~would~~duly ~~have~~ caused itthis toreport ~~make reference~~ to ~~the~~be ~~subject~~signed ~~matter~~on ~~of the disagreement(s) in connection with~~ its ~~report.~~behalf ~~During~~by the ~~Company’s~~ ~~most recent fiscal year and the subsequent interim period through March 23, 2023, there were no reportable events of the~~undersigned ~~type~~hereunder ~~described~~duly ~~in Item 304(a)(1)(v) of Regulation S-K~~authorized.

The Company has provided KCCW with a copy of the foregoing disclosure and requested KCCW to furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether it agrees with the statements made therein. A copy of such letter furnished by KCCW is filed as Exhibit 16.1 to this Form 8-K.

Date: May 8, 2023

	Tengjun Biotechnology Corp.

	By:	/s/ Xianchang Ma
		Xianchang Ma
		Chief Executive Officer

~~In connection with the foregoing, the Board approved the engagement of PWN LLP as the Company’s new independent registered public accounting firm.~~2

During the Company’s most recent fiscal years and the subsequent interim period through March 23, 2023, neither the Company nor anyone on its behalf consulted with PWN LLP regarding (i) the application of accounting principles to a specified transaction, either completed or proposed; the type of audit opinion that might be rendered on the Company’s financial statements, and neither a written report nor oral advice was provided that PWN LLP concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and its related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.

Exhibit No.		Description
16.1		Letter from KCCW Accountancy Corp. dated March 24, 2023

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Tengjun Biotechnology Corp.
Date: March 24, 2023	By:	/s/ Xianchang Ma
	Name:	Xianchang Ma
	Title:	Chief Executive Officer

Filing Compare · Tengjun Biotechnology Corp.